COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #46 of 230
5/27 Late treatment study
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Source   PDF   Share   Tweet
Study focused on remdesivir but with results for HCQ in the supplementary appendix, showing 9% death with HCQ versus 12% control, unadjusted relative risk uRR 0.78, p = 0.46.

Goldman et al., 5/27/2020, retrospective, multiple countries, multiple regions, peer-reviewed, 26 authors.
risk of death, 22.3% lower, RR 0.78, p = 0.46, treatment 10 of 109 (9.2%), control 34 of 288 (11.8%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.